ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Drop in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 197,000 shares, a drop of 24.7% from the March 15th total of 261,600 shares. Based on an average trading volume of 137,600 shares, the short-interest ratio is presently 1.4 days.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded down $1.23 on Friday, hitting $66.88. The company's stock had a trading volume of 94,984 shares, compared to its average volume of 139,273. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 79.62 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. ANI Pharmaceuticals has a 12 month low of $36.99 and a 12 month high of $70.81. The stock's 50-day moving average is $64.03 and its two-hundred day moving average is $58.38.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. On average, equities research analysts forecast that ANI Pharmaceuticals will post 3.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Truist Financial upped their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a "buy" rating in a report on Friday, March 1st. Capital One Financial started coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an "overweight" rating and a $80.00 target price on the stock. Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a "buy" rating in a report on Tuesday, March 5th. Finally, HC Wainwright boosted their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a "buy" rating in a research note on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $80.00.

Insiders Place Their Bets

In related news, CEO Nikhil Lalwani sold 28,965 shares of the business's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total value of $1,897,786.80. Following the completion of the sale, the chief executive officer now directly owns 444,981 shares of the company's stock, valued at $29,155,155.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Stephen P. Carey sold 7,787 shares of the firm's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.55, for a total value of $510,437.85. Following the transaction, the chief financial officer now directly owns 177,712 shares in the company, valued at approximately $11,649,021.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares of the company's stock, valued at $29,155,155.12. The disclosure for this sale can be found here. Insiders sold a total of 143,286 shares of company stock valued at $9,274,370 in the last ninety days. Corporate insiders own 28.50% of the company's stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank increased its position in shares of ANI Pharmaceuticals by 7.1% during the 1st quarter. Swiss National Bank now owns 27,000 shares of the specialty pharmaceutical company's stock valued at $759,000 after purchasing an additional 1,800 shares during the period. Citigroup Inc. raised its position in ANI Pharmaceuticals by 44.9% in the first quarter. Citigroup Inc. now owns 12,516 shares of the specialty pharmaceutical company's stock worth $352,000 after acquiring an additional 3,881 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in ANI Pharmaceuticals by 15.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,828 shares of the specialty pharmaceutical company's stock valued at $108,000 after acquiring an additional 512 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of ANI Pharmaceuticals by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 5,858 shares of the specialty pharmaceutical company's stock valued at $165,000 after purchasing an additional 2,127 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of ANI Pharmaceuticals by 4.4% in the 1st quarter. Rhumbline Advisers now owns 25,916 shares of the specialty pharmaceutical company's stock worth $728,000 after purchasing an additional 1,096 shares during the last quarter. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.